Stock A005250 GREEN CROSS HOLDINGS CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials Green Cross Holdings Corporation

Equities

A005250

KR7005250006

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-05-02 pm EDT 		5-day change 1st Jan Change
15,560 KRW -2.14% Intraday chart for Green Cross Holdings Corporation +1.90% -4.83%
May. 03 Green Cross Widens Q1 Loss, Sales Inch Up 2% MT
Mar. 20 Green Cross Holdings Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 1,137,466 1,009,178 1,904,748 1,238,276 775,668 745,892
Enterprise Value (EV) 1 1,658,608 1,662,963 2,481,633 1,885,666 1,633,562 1,829,947
P/E ratio 61.8 x 379 x 11.1 x 22.6 x 23.8 x -13.7 x
Yield 1% 1.46% 1.2% 1.47% 1.76% -
Capitalization / Revenue 0.73 x 0.66 x 1.11 x 0.67 x 0.37 x 0.36 x
EV / Revenue 1.07 x 1.09 x 1.44 x 1.02 x 0.79 x 0.89 x
EV / EBITDA 17.2 x 19 x 20.1 x 12.7 x 11 x 25.1 x
EV / FCF -21.2 x -13.7 x -27.1 x -52.3 x 2,448 x -10.2 x
FCF Yield -4.71% -7.28% -3.69% -1.91% 0.04% -9.84%
Price to Book 0.01 x 1.24 x 2.05 x 1.21 x 0.74 x 0.76 x
Nbr of stocks (in thousands) 45,402 45,402 45,402 45,402 45,402 45,402
Reference price 2 25,100 22,250 41,500 27,150 17,000 16,350
Announcement Date 3/19/19 3/17/20 3/17/21 3/21/22 3/21/23 3/20/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 1,548,715 1,524,799 1,719,326 1,840,559 2,079,560 2,057,936
EBITDA 1 96,594 87,330 123,495 148,443 148,876 73,017
EBIT 1 49,312 30,388 70,664 85,999 70,221 -21,830
Operating Margin 3.18% 1.99% 4.11% 4.67% 3.38% -1.06%
Earnings before Tax (EBT) 1 43,189 -13,760 107,919 180,013 29,629 -81,110
Net income 1 18,467 2,957 170,960 55,270 32,823 -54,136
Net margin 1.19% 0.19% 9.94% 3% 1.58% -2.63%
EPS 2 406.5 58.73 3,743 1,201 715.6 -1,198
Free Cash Flow 1 -78,148 -120,998 -91,539 -36,032 667.4 -179,994
FCF margin -5.05% -7.94% -5.32% -1.96% 0.03% -8.75%
FCF Conversion (EBITDA) - - - - 0.45% -
FCF Conversion (Net income) - - - - 2.03% -
Dividend per Share 2 250.0 325.0 500.0 400.0 300.0 -
Announcement Date 3/19/19 3/17/20 3/17/21 3/21/22 3/21/23 3/20/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 521,143 653,785 576,885 647,390 857,894 1,084,055
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 5.395 x 7.486 x 4.671 x 4.361 x 5.762 x 14.85 x
Free Cash Flow 1 -78,148 -120,998 -91,539 -36,032 667 -179,994
ROE (net income / shareholders' equity) 1.34% -2.06% 4.43% 7.12% 3.04% -3.72%
ROA (Net income/ Total Assets) 1.19% 0.7% 1.47% 1.6% 1.24% -0.37%
Assets 1 1,554,684 420,689 11,642,626 3,464,319 2,650,866 14,544,950
Book Value Per Share 2 1,720,377 17,903 20,248 22,473 22,857 21,591
Cash Flow per Share 2 536,409 3,887 9,858 7,354 4,595 3,844
Capex 1 117,998 138,929 108,477 116,600 73,216 89,962
Capex / Sales 7.62% 9.11% 6.31% 6.34% 3.52% 4.37%
Announcement Date 3/19/19 3/17/20 3/17/21 3/21/22 3/21/23 3/20/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
GREEN CROSS HOLDINGS CORPORATION Stock Green Cross Holdings Corporation
-4.83% 523M
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.85% 546B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.77% 359B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.97% 323B
ABBVIE INC. Stock AbbVie Inc.
+5.69% 290B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 234B
NOVARTIS AG Stock Novartis AG
+3.65% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-11.12% 194B
AMGEN INC. Stock Amgen Inc.
+8.08% 167B
PFIZER, INC. Stock Pfizer, Inc.
-3.40% 157B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A005250 Stock
  4. Financials Green Cross Holdings Corporation